While these multi-gene expression assays target specific subtypes of breast cancer, the TP53 signature focuses on the mutation status and expression profiles of TP53-associated genes, offering a targeted approach that may provide advantages in specificity and applicability across all breast cancer subtypes. This evidence concerns the gene TP53 and breast cancer.